This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What's in Store for Amgen (AMGN) This Earnings Season?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Otezla Repatha and other and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Eli Lilly (LLY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Higher demand for its growth drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) second-quarter sales.
Pharma Stock Roundup: Q2 Earnings of MRK, PFE & Others, FDA Approvals for GSK, ABBV
by Kinjel Shah
Pfizer (PFE), Merck (MRK) and others announce Q2 results. FDA approves AbbVie's (ABBV) new antibiotic injection and expands use of Merck's Keytruda and Glaxo's Shingrix and Nucala.
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $243.58, moving +0.15% from the previous trading session.
Eli Lilly (LLY) Reports Next Week: What You Should Expect
by Zacks Equity Research
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pharma Stock Roundup: JNJ, NVS Q2 Earnings, PFE, ABBV, LLY & MRK FDA Updates
by Kinjel Shah
J&J (JNJ) and Novartis (NVS) announce Q2 results. FDA delays decisions on JAK inhibitor drugs of Lilly (LLY), AbbVie (ABBV) and Pfizer (PFE) for eczema indication.
Pfizer (PFE) Inks Vaccine Deal, Faces FDA Delay on JAK Drugs
by Zacks Equity Research
Pfizer (PFE) partners with Biovac for manufacturing and distributing its COVID-19 vaccine in African Union. The FDA delays decision on Pfizer's regulatory filings for JAK inhibitors.
The Zacks Analyst Blog Highlights: Exxon Mobil, Eli Lilly, Costco, Aon and EOG Resources
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Exxon Mobil, Eli Lilly, Costco, Aon and EOG Resources
Top Stock Reports for Exxon Mobil, Eli Lilly & Costco
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil (XOM), Eli Lilly (LLY), and Costco Wholesale (COST).
AbbVie (ABBV) Rinvoq Dermatitis' sNDA Decision Delayed by FDA
by Zacks Equity Research
The FDA will not meet its action dates for AbbVie's (ABBV) sNDA for JAK inhibitor drug, Rinvoq (upadacitinib), for moderate to severe atopic dermatitis.
Lilly (LLY), Incyte's Decision on Olumiant sNDA Delayed by FDA
by Zacks Equity Research
The FDA will not meet the PDUFA action date for Lilly (LLY) and Incyte's (INCY) sNDA for Olumaint to treat adults with atopic dermatitis.
Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FLQL
Pharma Stock Roundup: NVO & LLY's Small Acquisitions, JNJ's Sunscreens Recall
by Kinjel Shah
Novo Nordisk (NVO) and Eli Lilly (LLY) announce small acquisition deals. J&J (JNJ) recalls some consumer products.
Lilly's (LLY) Protomer Acquisition to Expand Diabetes Pipeline
by Zacks Equity Research
Lilly (LLY), which holds a 14% stake in private biotech company Protomer, acquires the remaining interest in it. The acquisition is set to expand Lilly's diabetes pipeline.
Lilly (LLY) Stock Riding on Pipeline Developments This Year
by Zacks Equity Research
Lilly's (LLY) shares are up this year mainly due to positive developments related to its interesting pipeline of cancer, diabetes and Alzheimer's candidates.
Aridis' (ARDS) COVID Antibody Combo Neutralizes Delta Variant
by Zacks Equity Research
Aridis Pharmaceuticals' (ARDS) inhaled COVID-19 dual antibody cocktail treatment, AR-712, binds and neutralizes the Delta variant of the virus. Stock rises in after-hours trading.
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Pharma Stock Roundup: GSK's New Deal With Alector, MRK & AZN's FDA Updates
by Kinjel Shah
Glaxo (GSK) to co-develop Alector's two candidates for neurodegenerative diseases. FDA updates for Merck (MRK) and AstraZeneca (AZN)
SNY vs. LLY: Which Stock Is the Better Value Option?
by Zacks Equity Research
SNY vs. LLY: Which Stock Is the Better Value Option?
WHO Guidelines Put Spotlight on Arthritis Drugs Actemra & Kevzara
by Zacks Equity Research
The latest guideline update by the WHO includes the use of arthritis drugs like Roche's (RHHBY) Actemra and Sanofi's (SNY) Kevzara for the treatment of severe COVID-19.
Lilly's (LLY) Jardiance Heart Failure Study Meets Main Goal
by Zacks Equity Research
Lilly's (LLY) Jardiance significantly reduces the risk of the composite of cardiovascular death or hospitalization for heart failure in patients with heart failure with preserved ejection fraction.
The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer, BioNTech and Bayer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer, BioNTech and Bayer
3 Big Drugmakers Likely to be in Focus in Second Half of 2021
by Kinjel Shah
Eli Lilly (LLY), Pfizer (PFE) and Bayer (BAYRY) are three large drug sector companies worth buying and holding for the next few months and beyond.
The Zacks Analyst Blog Highlights: Google, Visa, Eli Lilly, Amgen and Sony Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Google, Visa, Eli Lilly, Amgen and Sony Group
Top Analyst Reports for Alphabet, Visa & Eli Lilly
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Visa (V), and Eli Lilly (LLY).